Evidence map›Paper›PMID 38846967›Full record

ArticleWorld journal of gastrointestinal pharmacology and therapeutics2024

Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP

Nathalie Talbodec, Pauline Le Roy, Peggy Fournier, Benoit Lesage, Elodie Lepoutre, François Castex, Jean Michel Godchaux, Lionel Vandeville, Benjamin Bismuth, Xavier Lesage and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal pharmacology and therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nathalie TalbodecDepartment of Gastroenterology, Hôpital privé Le Bois, Lille 59000, France.
Pauline Le RoyDepartment of Gastroenterology, Hôpital privé de Villeneuve d'Ascq, Villeneuve d'Ascq 59650, France.
Peggy FournierDepartment of Gastroenterology, Hôpital privé Le Bois, Lille 59000, France.
Benoit LesageDepartment of Gastroenterology, Hôpital privé Le Bois, Lille 59000, France.
Elodie LepoutreDepartment of Gastroenterology, Hôpital privé Le Bois, Lille 59000, France.
François CastexDepartment of Gastroenterology, Hôpital privé de Villeneuve d'Ascq, Villeneuve d'Ascq 59650, France.
Jean Michel GodchauxDepartment of Gastroenterology, Hôpital privé de Villeneuve d'Ascq, Villeneuve d'Ascq 59650, France.
Lionel VandevilleDepartment of Gastroenterology, Hôpital privé Le Bois, Lille 59000, France.
Benjamin BismuthDepartment of Gastroenterology, Hôpital privé Le Bois, Lille 59000, France.
Xavier LesageDepartment of Gastroenterology, Hôpital privé Le Bois, Lille 59000, France.
Pauline BayartDepartment of Gastroenterology, Hôpital privé Le Bois, Lille 59000, France.
Michael GeninUniv. Lille, CHU Lille, ULR 2694-METRICS, Évaluation des Technologies de Santé et des Pratiques Médicales, Lille 59000, France.
Christel RousseauxDevelopment of Intestinal Biotech, 1 Avenue Oscar Lambret, Lille 59045, France.
Veronique MaquetKitoZyme SA, Parc Industriel des hauts Sarts Zone 2, Rue de Milmort, Herstal 4040, Belgium.
Salvatore ModicaBiOkuris A, Parc Industriel des hauts Sarts Zone 2, Rue de Milmort, Herstal 4040, Belgium.
Pierre DesreumauxDepartment of Hepato-Gastroenterology, Lille University Hospital, Lille 59000, France.
Caroline ValibouzeDepartment of Digestive Surgery and Transplantation, Lille University Hospital, Lille 59037, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIrritable bowel syndrome (IBS), defined according to the Rome IV diagnostic criteria, is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain related to altered bowel habits. First-line recommended treatments are limited to combining drugs targeting predominant symptoms, particularly pain (antispasmodics), constipation (laxatives), and diarrhea (loperamide), yielding only a limited therapeutic gain. GASTRAP

aimTo evaluate the efficacy, tolerability, and safety of 4-week GASTRAP

methodsIn this prospective, multicenter, open-label trial, 120 patients with IBS received three sticks of GASTRAP

resultsOverall, 100 patients were evaluated. At W4, 67% (95%CI: 57-75) showed improvement in abdominal pain (score: 5.8 ± 2.4

conclusionGASTRAP

Indexed as

Abdominal painChitin-glucanDefecatory disordersFlatulenceIrritable bowel syndromeNatural non-pharmacological treatmentStool consistency

Identifiers

PMID38846967
PMCPMC11151880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.